Christopher Pierce, EVP and Chief of Business Oper at Prelude Therapeutics Inc (PRLD), sold 200 shares at $40.00 ($8K) on 2021-04-08, disclosed to the SEC on 2021-04-15.
Scheduled sale ($8k) by EVP and Chief of Business Oper under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| PRLD | SELL | 2021-04-09 | $33K | — | Filing → |
| PRLD | BUY | 2020-09-29 | $71K | — | Filing → |